PerkinElmer (NYSE:PKI) has had a great run on the share market with its stock up by a significant 18% over the last...

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for EUROIMMUN’s (a PerkinElmer company) Anti-SARS-CoV-2 ELISA (IgG) serology test. Clinical laboratories certified to perform high complexity tests under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ELISA for the detection of antibodies of the immunoglobulin class G.

PerkinElmer's (PKI) first-quarter results benefit from growth in Discover & Analytics Solutions segment. However, forex remains a woe.

Q1 2020 PerkinElmer Inc Earnings Call

PerkinElmer Inc. said Monday that it has not received any information, and is not aware of any wrongdoing, as implied by a Reuters report. The diagnostics and health services company also said it did not have any information that it or any of its personnel are being investigated by the government. The company's statement comes after Reuters reported, citing sources and documents reviewed by Reuters, that PerkinElmer faced a federal investigation into its role in an alleged Medicare fraud involving unnecessary genetic cancer tests. PerkinElmer acknowledged that it has received subpoenas, but they were regarding investigations into third parties. The company said it has fully cooperated with authorities. The stock rose 0.1% in morning trading. It has slipped 1.3% over the past three months, while the S&P 500 has lost 12.7%.

PerkinElmer (PKI) delivered earnings and revenue surprises of 42.55% and 1.75%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The Food and Drug Administration’s decision to crack down on a loose set of regulatory requirements for antibody tests follows concerns about test validity and fraud.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the first quarter ended April 5, 2020.

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of PerkinElmer, Inc. New York, May 15, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of PerkinElmer, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock on April 30, 2020. This dividend is payable on August 7, 2020 to all shareholders of record at the close of business on July 17, 2020.

Medical diagnostic firm PerkinElmer Inc faces a federal investigation into its role in an alleged Medicare fraud involving tens of thousands of unnecessary genetic cancer tests, according to three sources with knowledge of the probe and documents reviewed by Reuters. The firm conducted the tests now under scrutiny over 18 months, earning millions of dollars, according to one of those sources and three others familiar with the company's lab operations. Investigators are probing whether Massachusetts-based PerkinElmer enabled a scheme by some its laboratory clients, two of which the government previously has charged in connection with alleged Medicare fraud, said the three sources with knowledge of the probe.

Linde PLC tops the list Continue reading...

PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, gave notice today that in response to continued public health restrictions on in-person gatherings given the coronavirus/COVID-19 pandemic, the Board of Directors of PerkinElmer has determined to change the format of the company’s Annual Meeting of Shareholders scheduled for Tuesday, April 28, 2020, at 8:00 a.m. EST from in-person to virtual-only. The meeting will be webcast and can be accessed by stockholders at www.virtualshareholdermeeting.com/PKI2020 using the 16-digit control number on their proxy card, voting instruction form or Notice of Internet Availability. The company has designed the format of the Annual Meeting to ensure that shareholders are afforded the same rights and opportunities to participate as they would at an in-person meeting, using online tools to ensure shareholder access and participation. For additional information regarding accessing and participating in the virtual meeting, please refer to the company’s supplemental proxy materials filed with the Securities and Exchange Commission on April 14, 2020.

Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 PerkinElmer Earnings Conference Call. With me on the call are Prahlad Singh, President and Chief Executive Officer; and Jamey Mock, Senior Vice President and Chief Financial Officer. Statements or comments made on this call may be forward-looking statements, which may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual BofA Securities Virtual Healthcare Conference 2020 on Thursday, May 14, 2020 at 8:20 a.m. ET.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that on Tuesday, May 5, 2020, after market close, the Company will release first quarter 2020 results. The Company will also host a conference call the same day at 5:00 p.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Jamey Mock, senior vice president and chief financial officer, will host the conference call.

Beaumont Health's Research Institute is launching America's largest serological testing study to help answer many questions surrounding the spread of COVID-19 and potentially help treat patients battling the virus.

PerkinElmer, Inc. (NYSE: PKI) supports government efforts to identify and prevent abusive practices in healthcare. PerkinElmer has received subpoenas from the government regarding investigations into third parties, and has fully cooperated with authorities and will continue to do so. The Company is not aware of, and has not received any information regarding, wrongdoing by PerkinElmer, as implied by Reuters, nor does PerkinElmer have any information that the Company or any of our personnel are the target of a government investigation.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the (virtual) Jefferies Global Healthcare Conference on Thursday, June 4, 2020 at 9:00 a.m. ET.